NKTRHealthcare · BiotechnologyThe 11 Wall Street analysts covering Nektar Therapeutics hold a median 12-month price target of $151 — +113.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Nektar Therapeutics on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (89): The shares have been drifting up relative to others.
Accruals (12): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own Nektar Therapeutics — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on NKTR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +113.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 July 2026 | Canaccord Genuity | Initiates | Buy | $153 |
| 11 May 2026 | Wedbush | Maintains | Neutral | — |
| 11 May 2026 | Wedbush | Maintains | Neutral | $95 → $80 |
| 8 May 2026 | Piper Sandler | Maintains | Overweight | — |
| 8 May 2026 | Piper Sandler | Maintains | Overweight | $105 → $192 |
| 21 Apr 2026 | Citigroup | Maintains | Buy | — |
| 21 Apr 2026 | Wedbush | Maintains | Neutral | — |
| 20 Apr 2026 | BTIG | Maintains | Buy | — |
| 20 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Mar 2026 | Wedbush | Initiates | Neutral | — |
| 17 Mar 2026 | TD Cowen | Initiates | Buy | — |
| 16 Mar 2026 | Citigroup | Maintains | Buy | — |
| 23 Feb 2026 | B. Riley Securities | Reiterates | Buy | — |
| 10 Feb 2026 | BTIG | Maintains | Buy | — |
| 10 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Jan 2026 | BTIG | Reiterates | Buy | — |
| 16 Dec 2025 | BTIG | Maintains | Buy | — |
| 16 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Nov 2025 | Citigroup | Initiates | Buy | — |
| 26 Nov 2025 | Jefferies | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 6% of US stocks
Cheaper than 29% of US stocks
Cheaper than 88% of US stocks
Higher than 38% of US stocks
Higher than 42% of US stocks
Higher than 9% of US stocks
Higher than 1% of US stocks
Higher than 20% of US stocks
Higher than 23% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NKTR appears on the weeks it earns a place.
Nektar Therapeutics announced it will release its second quarter 2026 financial results after market close on August 13, 2026, and hold a conference call at 5:00 p.m. that day.
Why it matters — The earnings release and conference call will provide current financial performance and operational updates for NKTR.
Wall Street analysts have set an average price target for Nektar Therapeutics suggesting a potential 104% upside, though the article notes such targets can be questionable. The piece also highlights a positive trend in earnings estimate revisions for NKTR.
Why it matters — NKTR watchers would care because analyst price targets and earnings estimate revisions are signals that can influence investor perception, even if their reliability is debated.
Nektar Therapeutics granted non-qualified stock options to purchase 36,000 shares of common stock to 23 newly-hired employees under its 2025 Inducement Plan, approved by the Board on July 20, 2026.
Why it matters — The inducement grants signal Nektar is actively hiring new talent, which could indicate ongoing investment in its pipeline and operations.
The 11 Wall Street analysts covering Nektar Therapeutics have a median 12-month price target of $151, with estimates ranging from $80 to $192. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Nektar Therapeutics, 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nektar Therapeutics 52 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Nektar Therapeutics ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (89 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +113.9% from the last close, and Ticker Nerd's factor model ranks Nektar Therapeutics 52 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Nektar Therapeutics publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NKTR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $192 over the next 12 months.
Nektar Therapeutics returned +207.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Nektar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders and chronic inflammatory diseases in the United States and internationally.
The most recent item we track (PRNewsWire, 28 July 2026): "Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets". Nektar Therapeutics announced it will release its second quarter 2026 financial results after market close on August 13, 2026, and hold a conference call at 5:00 p.m. that day.
Nektar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders and chronic inflammatory diseases in the United States and internationally. Its lead product candidate, rezpegaldesleukin (also known as REZPEG or NKTR-358), is a novel regulatory T cell stimulator and IL-2 pathway agonist designed to restore immune system balance in conditions such as moderate-to-severe atopic dermatitis, severe-to-very-severe alopecia areata, and Type 1 diabetes mellitus. The company is advancing rezpegaldesleukin through Phase 2b clinical trials, including the REZOLVE-AD and REZOLVE-AA studies, which evaluate subcutaneous injections for efficacy in disease control and patient outcomes. Beyond its lead asset, Nektar Therapeutics Inc. maintains a pipeline of investigational programs targeting immune pathways, such as a preclinical bivalent tumor necrosis factor receptor type II agonist, bispecific molecules NKTR-0165 and NKTR-0166, a modified hematopoietic colony stimulating factor protein NKTR-422, and NKTR-255, an IL-15 receptor agonist developed in collaboration for oncology applications to enhance anti-tumor immune responses. Founded in 1990 and headquartered in San Francisco, California, Nektar Therapeutics Inc. leverages expertise in polymer chemistry and immunology to create highly selective medicines addressing unmet needs in immunotherapy.
CEO Mr. Howard W. Robin · 63 employees · United States · https://www.nektar.com